NanoViricides Inc. (NNVC.OB) Announces Positive Results in Animal Studies for Dengue Virus
NanoViricides Inc., a development-stage company focused on special purpose nanomaterials for viral therapy, today announced that its anti-Dengue drug candidates demonstrated positive results in the initial animal survival studies of Dengue virus infection. The Dengue virus, a member the family of viruses that includes West Nile and Hepatitis C viruses, is transmitted to humans through female Aedes mosquitoes. According to the World Health Organization, fatality rates of Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) can exceed 20 percent. WHO also reports that Dengue threatens more than 40 percent of the world population, and that Dengue cases with significant fatality rates are…